SBRT has non-inferior acute and late-term toxicity vs IMRT in two randomized clinical trials

In October 2018, the American Society of Radiation Oncologists (ASTRO) strongly endorsed moderately hypofractionated IMRT (20 or 28 treatments) for primary radiation treatment (see this link). … READ MORE …

ASTRO, ASCO, and AUA strongly endorse shortened course of IMRT for primary therapy

It will come as no surprise to our readers that moderately hypofractionated IMRT (first-line radiation delivered in 20 to 26 treatments or fractions instead of the conventional 40-44 fractions) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. … READ MORE …

Eighth randomized clinical trial of hypofractionated radiation therapy

We now have data from an eighth randomized clinical trial of hypofractionated radiation therapy. There are no surprises: … READ MORE …

No need to endure 38 to 44 treatments with IMRT anymore

There have been several hypofractionation trials maturing in the last couple of years. With minor exceptions, they all tell the same story: external beam radiation therapy (EBRT) can be completed in less time without loss of efficacy or increase in toxicity. … READ MORE …

Sexual function no worse when fewer external beam radiation treatments used

The HYPRO trial was designed to detect whether hypofractionation (fewer radiation treatments) was inferior to conventional fractionation (over about 8 weeks of treatment). … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

Hypofractionated radiation therapy for localized prostate cancer: an update

Within the past year, we have reviewed several major randomized clinical trials comparing hypofractionated radiation therapy to conventionally fractionated radiation therapy for primary treatment of localized prostate cancer. … READ MORE …